B Cell Deficiency in Patients with Relapsed and Refractory Acute Myeloid Leukemia

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
B Cell Deficiency in Patients with Relapsed and Refractory Acute Myeloid Leukemia ; volume:2 ; number:3 ; day:29 ; month:7 ; year:2020 ; pages:125-128 ; date:9.2020
Clinical hematology international ; 2, Heft 3 (29.7.2020), 125-128, 9.2020

Creator
Goswami, Meghali
Lindblad, Katherine E.
Ramraj, Rahul
Dagur, Pradeep K.
Thompson, Julie
McCoy, J. Philip
Hourigan, Christopher S.
Contributor
SpringerLink (Online service)

DOI
10.2991/chi.k.200712.001
URN
urn:nbn:de:101:1-2405020835211.658798259871
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:47 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Goswami, Meghali
  • Lindblad, Katherine E.
  • Ramraj, Rahul
  • Dagur, Pradeep K.
  • Thompson, Julie
  • McCoy, J. Philip
  • Hourigan, Christopher S.
  • SpringerLink (Online service)

Other Objects (12)

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia

Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia

Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia

Treatment of Relapsed Acute Myeloid Leukemia

Treatment of Relapsed Acute Myeloid Leukemia

Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia

Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia

Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia

Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy

CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia

CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia

Related objects